You are here
New strategies to target the androgen receptor
Christopher P. Evans
With a better understanding of the pathways resulting in castration resistance in prostate cancer, novel therapeutic agents that target the androgen receptor have been developed. Alternatives to new steroidogenesis inhibitors such as galeterone are compounds that block the non-ligand binding domain of the androgen receptor gene. For example EPI-001 that target the N-terminal domain thereby inhibiting gene transcription or VPC-14449 that effects splice variants by binding to the DNA-binding domain. Professor Christopher Evans considers further epigenomic regulation with methylation modifiers such as SD70 or targeting ROR-γ to suppress androgen receptor expression.